Brokerages Anticipate Zosano Pharma Corp (ZSAN) Will Announce Earnings of -$0.30 Per Share

Wall Street brokerages expect Zosano Pharma Corp (NASDAQ:ZSAN) to post earnings of ($0.30) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Zosano Pharma Corp’s earnings, with the lowest EPS estimate coming in at ($0.43) and the highest estimate coming in at ($0.17). Zosano Pharma Corp posted earnings per share of ($0.68) during the same quarter last year, which would indicate a positive year-over-year growth rate of 55.9%. The company is expected to announce its next earnings report after the market closes on Tuesday, May 9th.

According to Zacks, analysts expect that Zosano Pharma Corp will report full year earnings of ($0.87) per share for the current fiscal year, with EPS estimates ranging from ($0.95) to ($0.78). For the next financial year, analysts expect that the business will post earnings of ($0.79) per share, with EPS estimates ranging from ($0.92) to ($0.65). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Zosano Pharma Corp.

Zosano Pharma Corp (NASDAQ:ZSAN) last announced its earnings results on Wednesday, March 1st. The biotechnology company reported ($0.46) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by $0.01.

Several equities analysts recently weighed in on ZSAN shares. Piper Jaffray Companies started coverage on shares of Zosano Pharma Corp in a report on Friday, March 24th. They issued an “overweight” rating and a $4.00 price objective on the stock. Zacks Investment Research lowered shares of Zosano Pharma Corp from a “buy” rating to a “hold” rating in a report on Wednesday, January 18th. Finally, Roth Capital set a $3.00 target price on shares of Zosano Pharma Corp and gave the stock a “buy” rating in a report on Tuesday, February 14th.

TRADEMARK VIOLATION WARNING: This piece was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at

Shares of Zosano Pharma Corp (NASDAQ:ZSAN) traded down 2.56% during midday trading on Tuesday, reaching $1.45. The company had a trading volume of 937,350 shares. The firm’s 50 day moving average price is $1.64 and its 200-day moving average price is $1.31. Zosano Pharma Corp has a 12 month low of $0.45 and a 12 month high of $3.54. The company’s market capitalization is $28.20 million.

In related news, major shareholder Enterprise Associates 12 New sold 1,099,996 shares of the firm’s stock in a transaction on Monday, February 13th. The shares were sold at an average price of $2.01, for a total transaction of $2,210,991.96. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 5.37% of the company’s stock.

A hedge fund recently raised its stake in Zosano Pharma Corp stock. Armistice Capital LLC raised its position in shares of Zosano Pharma Corp (NASDAQ:ZSAN) by 43.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,200,000 shares of the biotechnology company’s stock after buying an additional 362,000 shares during the period. Armistice Capital LLC owned 7.14% of Zosano Pharma Corp worth $936,000 at the end of the most recent reporting period. 41.11% of the stock is owned by institutional investors.

About Zosano Pharma Corp

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

5 Day Chart for NASDAQ:ZSAN

Get a free copy of the Zacks research report on Zosano Pharma Corp (ZSAN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Zosano Pharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corp and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply